Verge Genomics
A clinical-stage biotech company transforming drug discovery using artificial intelligence (AI) and patient tissue data.
Verge is focused on developing therapeutics for complex diseases with high unmet need, using human genomics from patient disease tissues and machine learning.
The company has created a proprietary all-in-human CONVERGE platform, featuring one of the field’s largest and most comprehensive databases of multi-omic patient data.
Latest Verge Genomics News & Features
25 March 2024
9 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze